Istituto Ortopedico Rizzoli

Quick facts

Marketed products

• ACP · Orthopedics / Regenerative Medicine
  ACP is an autologous chondrocyte product that replaces damaged cartilage by implanting the patient's own cultured cartilage cells into the defect site.
• autologous bone marrow concentrate
• Bone marrow aspirate concentrate injection
• bone substitute i-FactorTM · Orthopedics / Bone regeneration
  i-Factor is a bone substitute that promotes bone regeneration by providing a scaffold and delivering osteoinductive signals to stimulate new bone formation.
• Injection of autologous concentrated bone marrow aspirate
• injection of hyaluronic acid. · Orthopedics / Rheumatology
  Hyaluronic acid injection acts as a viscoelastic lubricant and anti-inflammatory agent that restores joint fluid properties and reduces cartilage degradation.
• viscosupplementation · Other

Phase 3 pipeline

• Bone Marrow Concentrate · Orthopedics / Regenerative Medicine
  Bone marrow concentrate delivers a heterogeneous population of stem cells and growth factors to promote tissue regeneration and repair.

Phase 1 pipeline

• Vertebral bone marrow clot

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Istituto Ortopedico Rizzoli portfolio CI brief
• Istituto Ortopedico Rizzoli pipeline updates RSS

Frequently asked questions about Istituto Ortopedico Rizzoli

Related

• ACP · Orthopedics / Regenerative Medicine
• autologous bone marrow concentrate
• Bone marrow aspirate concentrate injection
• bone substitute i-FactorTM · Orthopedics / Bone regeneration
• Injection of autologous concentrated bone marrow aspirate
• Sector hub: All tracked pharma companies